Hyperpolarized MRI for Brain Tumor
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the treatment Hyperpolarized Carbon C 13 Pyruvate for brain tumors?
Research shows that hyperpolarized Carbon C 13 Pyruvate can help detect treatment responses in brain tumors by tracking changes in tumor metabolism, which is useful for early identification of treatment effectiveness. This method has been effective in other cancers, like breast cancer, by providing detailed metabolic information that can guide treatment decisions.12345
Is hyperpolarized MRI using carbon-13 pyruvate safe for humans?
How does the treatment Hyperpolarized MRI for Brain Tumor differ from other treatments for this condition?
Hyperpolarized MRI for brain tumors is unique because it uses a special form of MRI with hyperpolarized carbon-13 pyruvate to visualize and measure the metabolism of brain tumors in real-time. This method provides detailed metabolic information that can help assess tumor activity and response to treatment, which is not possible with standard imaging techniques.124910
What is the purpose of this trial?
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
Research Team
Susan Chang, MD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
This trial is for adults over 18 with a life expectancy of more than 12 weeks and diagnosed with glioma, who are not HIV-positive, pregnant or breastfeeding. Participants must have adequate kidney function, no severe heart failure or recent heart attacks, and no other cancers except certain skin cancers or cervical carcinoma in-situ unless in remission for at least 3 years.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Injection
Participants receive one or two hyperpolarized carbon C 13 pyruvate injections intravenously and undergo MRI
Treatment
Participants in Cohort II receive standard radiation and temozolomide treatment outside of this study
Post-Treatment Imaging
Participants in Cohort II undergo MRI 4 weeks after completion of cancer therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Hyperpolarized Carbon C 13 Pyruvate
- Magnetic Resonance Imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Susan Chang
Lead Sponsor
National Cancer Institute (NCI)
Collaborator